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Background: We investigated the efficacy, safety and 
tolerability of once-monthly administration of C.E.R.A. 
in erythropoiesis stimulating agents (ESAs) naive predi-
alysis patients with CKD for anemia treatment
Study Design: Single arm, open label study.
Methods: A total of 75 patients (mean (SD) age was 52.8 
(16.4) years, 76.0% were female) were included in this 
study conducted between 12 August 2008 and 30 Octo-
ber 2009 in 9 centers across Turkey. The mean change in 
Hb concentration (g/dL) between baseline (week 0) and 
the efficacy evaluation period (EEP) was the primary ef-
ficacy parameter evaluated in three consecutive periods 
including a dose titration period (DTP; with initial 1.2 
μg/kg dose of C.E.R.A., subcutaneously, 28 weeks), EEP 
(8 weeks) and a long-term safety period (16 weeks). 
Results: Our analysis revealed an improvement in Hb 
levels from baseline value of 9.4 (0.4) g/dL to time ad-
justed average level of 11.4 (0.7) g/dL in EEP in the 
per protocol (PP) population and from 9.3 (0.5) g/dL to 
11.1 (1.0) g/dL in intent-to-treat (ITT) population. Mean 
(SD) change in Hb levels from baseline to EEP was 2.0 
(0.7) g/dl in the PP population (primary endpoint) and 
1.7 (1.1) g/dL in the ITT population. The percentage of 
patients whose Hb concentrations remained within the 
target range of 10.0-12.0 g/dL throughout the EEP was 
43.9% (95% CI: 28.5-60.3%) in the PP population and 
38.7% (95% CI: 27.6% to 50.6%) in the ITP popula-
tion. A total of 206 adverse events (AE) were reported in 
77.0% of patients with hypertension (20%) as the most 
frequent AE. 
Conclusion: Once-monthly subcutaneous C.E.R.A. 
administration is effective and safe in the treatment of 
anemia in pre-dialysis patients with CKD, who are not 
currently treated with ESAs. 
Keywords: C.E.R.A., chronic kidney disease, efficacy, 
hemoglobin levels, safety, tolerability 
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The likelihood of overt anemia increases as the glomeru-
lar filtration rate (GFR) declines below 60 mL/min in patients 
with chronic kidney disease (CKD) (1). Exogenous replace-
ment of erythropoietin is now a well-accepted therapy in CKD 
(2,3) along with growing interest in the use of erythropoiesis 
stimulating agents (ESAs) (4). Continuous erythropoietin re-
ceptor activator (C.E.R.A.; F. Hoffmann-La Roche AG, Tur-
key) is an ESA developed by attaching a pegylation chain on 
to epoetin beta, which markedly prolonged the circulating 
half-life of the molecule to around 130 hours, allowing ad-
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ministration of the drug at extended intervals in the correction 
as well as maintenance periods (5,6).
Our study was designed to investigate the efficacy, safety 
and tolerability of monthly administration of C.E.R.A. in pre-
dialysis patients with chronic renal anemia (CRA) who are not 
currently treated with ESAs for the correction and subsequent 
maintenance of hemoglobin (Hb) concentrations. 
MATERIALS AND METHODS
Seventy-five patients (mean(SD) age: 52.8(16.4) years, 
76.0% females) were included in this single arm, open la-
bel study conducted between 12 August 2008 and 30 Octo-
ber 2009 in nine tertiary nephrology centers across Marmara 
(Edirne, Istanbul), Central Anatolia (Ankara, Konya), South-
eastern Anatolia (Diyarbakir) and Aegean (Denizli) Regions 
of Turkey. Patients aged ≥18 years, diagnosed with CRA, Hb 
levels of 8.5-10.0 g/dL, adequate iron status (serum ferritin 
and transferrin saturation >100 ng/mL and >20%, respective-
ly), no prior ESA therapy for three months prior to enrollment, 
followed as an outpatient (non-hospitalized) and at pre-dialy-
sis stage (GFR <30mL/min) were included. Exclusion criteria 
are shown in Table 1. 
Written informed consent was obtained from each subject 
and the protocol of the study was conducted in accordance 
with the ethical principles stated in the “Declaration of Hel-
sinki” and approved by the institutional ethics committee of 
the coordinator center.
Study visits and data collection
Eligible patients were enrolled at week 0. Patients then en-
tered a 28-week dose titration period (DTP). The DTP was 
followed by an 8-week efficacy evaluation period (EEP) and 
then a 16-week long-term safety period (LTSP).
Primary efficacy parameter
The primary efficacy parameter was the mean change in Hb 
concentration (g/dL) between baseline (week 0) and EEP. The 
mean Hb concentration for each individual patient during the 
EEP was estimated as a time adjusted average (Hi: Hb value 
at time-point; ti: study day; t0=first day of EEP; tn=last day of 
EEP; Σ: Total) by  . 
The successive changes in Hb during all study period were 
defined by: .
Secondary efficacy parameters
The percentage of patients whose Hb concentration re-
mained within the target range of 10.0-12.0 g/dL, the mean 
time (days) spent in the target range and the time (days) to 
achievement of response during EEP were amongst the sec-
ondary efficacy parameters. Others included the proportion 
of patients requiring dose adjustments during dose titration 
and evaluation periods as well as the documentation of RBC 
transfusions administered during the study in cases of medical 
need with respect to indications, specified by type, number of 
units transfused, total volume transfused and pre-transfusion 
Hb level. 
C.E.R.A. treatment
C.E.R.A. was administered subcutaneously every four 
weeks, i.e. weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44 
• Transfusion of red blood cells during the two months prior to enrollment
• Poorly controlled hypertension (systolic/diastolic BP of 170/100 mmHg 
in the sisstig position despite antihypertensive mediations and require-
ment for hospitalization in the last 6-months)
• Significant acute or chronic bleeding (e.g. Overt gastrointestinal bleed-
ing)
• Active malignant disease (except non-melanoma skin cancer)
• Hemolysis (based on identification of haptoglobin levels <30 mg/dL 
(3.54 µmol/L)or results of any reliable hemolysis test) 
• Hemoglobinopathies (e.g. Homozygous Sickle cell anemia, all types of 
thalassemia)
• Folic acid deficiency (not corrected within the last 2-month period and 
based on local laboratory findings such as erythrocyte MCV 105 fl)
• Vitamin B12 deficiency (not corrected within the last 2-month period and 
based on local laboratory findings such as erythrocyte MCV 105 fl)
• Thrombocyte count > 500x109/L or <100x109/L
• Pure red blood cell aplasia
• Epileptic seizure during previous six months
• Congestive heart failure (NYHA Class IV)
• Myocardial infarction or stroke, severe or unstable coronary artery dis-
ease, severe liver disease at investigator’s discretion, during the previous 
three months
• Uncontrolled or symptomatic secondary hyperparathyroidism at investi-
gator’s discretion
• Pregnancy or lactation period
• Women of child bearing potential with no effective contraceptive method 
•  Participation in another clinical trial or receiving any study product or 
treatment in the previous 3 months
• Known hypersensitivity to recombinant human erythropoietin, polyethyl-
ene glycol or to any constituent of the study medication, 
• Planned (date) elective surgery during the study period except for cata-
ract surgery or vascular access surgery.
TABLE 1. Exclusion criteria of the study
but not in weeks 48 and 52, after all visit specific assessments 
were done. 
The initial dose was selected as 1.2 μg/kg subcutaneously 
every four weeks. Initial dosing and all subsequent adjust-
ments were made using the nearest available Pre-filled Sy-
ringe (PFS) or combination of PFSs. Dose adjustment was not 
performed more frequently than once every four weeks while 
Hb >12 g/dL, <10 g/dL or Hb changes of more than 2 g/dL per 
month were avoided. 
Once the patient achieved Hb concentration within the tar-
get range, dose adjustments after achievement of response 
were made to maintain the individual patients’ Hb between 
10.0 and 12.0 g/dL.
Statistical analysis
All screened patients (n=75) received at least one C.E.R.A. 
dose, and were included in safety analysis and intent-to-treat 
(ITT) analysis populations, while only 41 patients were in-
cluded in per protocol (PP) analysis population. Data were ex-
pressed as “mean ± standard deviation (SD)”, percent (%) and 
median (min-max) where appropriate. 
Statistical analysis was performed using SPSS computer 
software (version 13.0, SPSS Inc. Chicago, IL, USA).
RESULTS
Study population
Fifty-one patients (68%) completed the prescribed course 
of C.E.R.A. medication. Premature withdrawal (n=24) was 
due to adverse events in 14 patients, protocol violation in 7 
patients, other reasons including renal transplantation (n=1) 
and dialysis initiation (n=1) in two patients and administrative 
reasons in one patient (Fig 1). 
Of the 75 patients who completed a baseline visit, 57 com-
pleted the titration period. Fifty-four out of 57 patients com-
pleted the evaluation period, and 51 completed the LTSP. 
While 51 patients completed the LTSP, only 41 were included 
in the PP analysis population, since 10 patients could not be 
included in the PP population due to presence of less than 
3 recorded Hb values during the efficacy evaluation period, 
missed CREA administration during weeks 28-36 or inade-
quate iron status (mean serum ferritin ≤100 ng/mL or TSAT 
≤20% or hypochromic RBCs <10%) (Figure 1).
Demographic data and baseline characteristics related to he-
mogram and iron parameters are summarized in Table 2.
Primary efficacy parameter
In the PP population, the mean (SD) Hb level at baseline 
was 9.4 (0.4) g/dL. The time adjusted average of Hb during 
the EEP was 11.4 (0.7) g/dL. The mean (SD) change in Hb 
concentration between baseline and EEP was 2.0 (0.7) g/dL 
(Table 3).
Confirming the results in the PP population, in the ITT pop-
ulation, the mean change in Hb concentration between base-
line and EEP was 1.7 (1.1) g/dL with Hb at baseline of 9.3 
(0.5) g/dL and the time adjusted average of Hb during the EEP 
of 11.1 (1.0) g/dL (Table 3).
Mean Hb levels in safety population throughout the study 
are presented in Figure 2.
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FIG. 1. Patient disposition
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Secondary efficacy parameters
The percentage of patients whose Hb concentrations remained 
within the target range of 10.0-12.0 g/dL throughout the EEP 
was 43.9 (18 out of 41 patients) with a 95% Clopper-Pearson 
confidence interval from 28.5% to 60.3%. In the ITT population, 
the result was 38.7% (29 out of 75 patients) with a 95% Clopper-
Pearson confidence interval from 27.6% to 50.6% (Table 3).
The percentage of patients whose time adjusted average Hb 
remains within the target range of 10.0-12.0 g/dL throughout 
the EEP was 73.2% (30 out of 41 patients) with a 95% Clop-
per-Pearson confidence interval from 57.1% to 85.8%. In the 
ITT population, the result was 54.7% (41 out of 75 patients) 
with a 95% Clopper-Pearson confidence interval from 42.8% 
to 66.2% (Table 3). 
The mean (SD) time spent in the target range of 10.0-12.0 
g/dL during the EEP was calculated to be 40.6 (16.3) days in 
the PP population and 39.8 (18.2) days in the ITT population. 
During the DTP, the mean time spent in the target ranges in the 
PP and ITT populations were 131.6 (43.4) and 109.6 (53.2) 
days, respectively. During the LTSP, the mean time spent in 
the target range was 61.1 (24.0) days in the PP population and 
59.9 (24.4) days in the ITT population (Table 3).
The mean (SD) times for achievement of response in the PP 
and ITT populations were 24.2 (21.0) and 28.4 (26.0) days, 
respectively (Table 3).
Dose adjustments
The initial drug dose was patient weight x1.2 μg. During the 
DTP, dose adjustment was necessary in 35 out of 41 patients 
(85.4%) in the PP population (Table 2). In the ITT population 
during the DTP, dose adjustment was necessary in 62 patients 
(82.7%) (Table 3).
All 41 patients in the PP population entered the EEP. The 
drug dose needed to be adjusted in 23 patients (56.1%). Fifty-
seven patients out of 75 patients included in the ITT popula-
tion entered the EEP. The drug dose had to be adjusted in 28 
patients (49.1%) (Table 3). In the PP population, all 41 pa-
tients entered the LTSP. The drug dose needed to be adjusted 
in 24 patients (59%) (Table 3).
 Mean (SD)




Baseline hematologic findings Mean (SD)
Hb (g/dL) 9.3 (0.5)
Erythrocyte MCV (fL) 88.0 (7.6)
Hct (fraction) 0.28 (0.0)
Ferritin concentration (μg/L) 281.6 (163.1)
Transferrin saturation (%) 37.2 (42.2)
Iron concentration (μmol/L) 14.4 (10.3)
Total iron-binding capacity (μmol/L) 44.1 (12.6)
CRP concentration (mg/L) 8.8 (12.8)
White blood cell count (109/L) 7.3 (2.1)
Thrombocyte count (109/L) 252.1 (82.6)
Etiology of CKD* n (%)
Diabetes mellitus 27 (36.3)
Hypertension/large vessel disease 25 (33.3)
Interstitial nephritis/pyelonephritis 10 (13.3)
Glomerulonephritis 5 (6.7)
Polycystic kidney disease 5 (6.7)
Risk factors*  n (%)
Arterial Hypertension 61 (81.3)
IDDM  15 (20.0)
NIDDM  15 (20.0)
Hyperlipidemia  15 (20.0)
PTCA  7 (9.3)
Myocardial infarction  5 (6.7)
*observed in ≥5% of the patients.
CKD: chronic kidney disease; Hb: hemoglobin; Hct: hematocrit; CRP-C-reactive 
protein; IDDM: insulin-dependent diabetes mellitus; NIDDM: non-insulin-dependent 
diabetes mellitus; MCV: mean corpuscular volume; PTCA: percutaneous transluminal 
coronary angiography
TABLE 2. Patient demographics, baseline etiological and clinical 
characteristics in the safety population (n=75)

















































































In the ITT population, 54 patients entered the LTSP. 
The drug dose needed to be adjusted in 29 patients (54%) 
(Table 3).
Hb concentration from baseline to DTP or LTSP
Between baseline and DTP, the mean (SD) changes in Hb 
concentration in the PP and ITT populations were 1.8 (0.6) 
g/dL and 1.6 (0.8) g/dL, respectively. Between baseline and 
LTSP, the mean (SD) change in Hb concentration was 1.9 
(0.8) g/dL in the PP population, and 1.6 (1.2) g/dL in the ITT 
population (Table 3).
Safety results- extent of exposure to trial medication
The mean (SD) cumulative total dose up to week 44 was 
1016 (720.2) µg, and the median was 802.5 µg. The mean 
(SD) C.E.R.A. monthly dose was calculated to be 87.8 (47.0) 
μg during the DTP, 82.8 (76.3) μg during the EEP, and 78.0 
(75.1) during the LTSP. The median dose decreased from 79 
μg/mo during DTP, to 68 μg/mo during EEP, and to 60 μg/mo 
during LTSP (Table 4).
Safety results-adverse events (AEs)
Seventy-seven percent of the patients reported 206 AEs 
starting during treatment. The most frequently recorded AEs 
were hypertension (20%) and hyperkalemia (12%). A to-
tal of 37 drug-related AEs occurred in 21 (28.0%) patients. 
The most frequently recorded related AEs were hypertension 
(6.7% of all patients), blood pressure increased (5.3%), hyper-
kalemia (5.3%), hyperphosphatemia (5.3%), nausea (2.7%) 
and pruritus (2.7%). All other related AEs were occurred with 
a frequency less than or equal to 1.3% (Table 5).
Thirty serious adverse events were reported in 24 patients. 
Edema and thrombocytosis were the two serious adverse 
events considered to be drug-related, while resolved and re-
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 PP population (n=41)  ITT population (n=75)
Primary efficacy parameters Mean (SD)  Mean (SD)
Hb level at baseline (g/dL) 9.4 (0.4)  9.3 (0.52)
Time adjusted Hb level during EEP (g/dL) 11.4 (0.7)  11.1 (1.0)
Change in Hb (baseline to EEP) (g/dL) 2.0 (0.7)  1.7 (1.1)
Secondary efficacy parameters n (%)  CI (min; max) n (%)  CI (min; max)
% with Hb in the target range*  18 (43.9)  28.5; 60.3 29 (38.7)  27.6; 50.6
% with time adjusted Hb in TR*  30 (73.2)  57.1; 85.8 41 (54.7) 42.8; 66.2
Time spent in Hb TR* (days)  Mean (SD)  Mean (SD)
During DTP 131.6 (43.4)  109.6 (53.5)
During EEP 40.6 (16.3)  39.8 (18.2)
During LTSP 61.1 (24.0)  59.9 (24.4)
Time to response during EEP (days) 24.2 (21.0)  28.4 (26.0)
Need for dose adjustments n (%)  n (%)
During DTP 35 (85.4)  62 (82.7)
During EEP 23 (56.1)  28 (49.1) (n=57)
During LTSP 24 (59.0)  29 (54.0) (n=54)
Change in Hb concentration (g/dL) Mean (SD)  Mean (SD)
Between baseline and DTP 1.8 (0.6)  1.6 (0.8)
Between baseline and LTSP 1.9 (0.8)  1.6 (1.2)
* TR: target range = 10.0-12.0 g/dL 
CI: Clopper-Pearson confidence interval; Hb: hemoglobin; DTP: dose titration period; EEP: efficacy evaluation period; LTSP: long-term safety period
TABLE 3. Efficacy parameters
Extent of exposure to trial medication Mean (SD)
Cumulative dose up to week 44 (μg) 1016 (720.2)
C.E.R.A monthly dose (μg) Mean (SD) Median 
During DTP 87.8 (47.0) 79
During EEP 82.8 (76.3) 68
During LTSP 78.0 (75.1) 60
C.E.R.A.: continuous erythropoietin receptor activator; DTP: dose titration period; 
EEP: efficacy evaluation period; LTSP: long-term safety period
TABLE 4. Extent of exposure to trial medication
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covered with sequelae, respectively. Twenty-four serious ad-
verse events started during the DTP, four SAEs occurred dur-
ing the EEP, and two SAEs started during the LTSP. 
Seventeen patients withdrew from the study due to adverse 
events. A summary of all adverse events leading to treatment 
withdrawal is provided in Table 5. Twenty-one adverse events 
in 19 patients led to dose modifications (all screened patients). 
The most common adverse event leading to dose adjustment 
was hypertension (11 events).
Safety results- hematology, blood biochemistry, iron 
parameters and other laboratory findings
Compared to baseline Hb values increased by 2 g/dL (mean 
(SD) from 9.3 (0.5) at baseline to 11.0 (0.8) g/dL at week 48) 
(Figure 2). For other hematologic laboratory parameters no 
obvious tendencies in the differences from baseline could be 
observed during the study. Similarly, no significant changes 
occurred in blood chemistry and iron parameters during the 
study (Table 6).
DISCUSSION
Use of C.E.R.A. at extended intervals has been inherently 
suitable given its long half-life, slow systemic clearance and 
low affinity for erythropoietin receptors (4,7). Data from clini-
cal studies (8-13) suggest safe and effective use of C.E.R.A. 
every 2-4 weeks and once-monthly for correction and main-
tenance therapy, respectively, in anemic predialysis (8,10,12-
17) or dialysis (9,11,18-20) CKD patients. 
Data from the ARCTOS (Administration of C.E.R.A. in 
CKD Patients to Treat Anemia with a Twice-Monthly Sched-
ule) study revealed that once every 2 weeks subcutaneous 
C.E.R.A. was associated with improved Hb levels and thus 
amelioration of anemia in ESA-naïve non-dialysis CKD pa-
tients, while once-monthly administration maintained stable 
Hb levels during the 24-week extension period (12). The 
CORDATUS study (Correction of Renal Anemia in CKD Pa-
tients with Subcutaneous Therapy) also showed efficacy of 
C.E.R.A. in anemia correction in non-dialysis CKD patients 
along with a safety profile comparable to darbepoetin alpha 
(10). Efficacy and safety of C.E.R.A. was also reported in pre-
dialysis patients with significant increases in Hb levels within 
6-12 months of therapy (13,17). Once every 2 week subcuta-
neous C.E.R.A. in ESA-naïve predialysis CKD patients was 
reported to be associated with a 2.15 g/dL increase in Hb con-
centrations within the 28-week follow up along with similar 
efficacy of the drug within a further 24-week extension pe-
riod either under every 2 or 4 week regimen (15). Switching 
of treatment from once weekly darbopoetin alpha to monthly 
C.E.R.A. was reported to be associated with an increase in the 
rate for success in correction of anemia in a year from 75.7% 
to 80% in anemic predialysis patients (16). 
Notably, albeit pre-dialysis patients in our cohort were 
younger (53 years vs. 66-70 years) and composed predomi-
Safety Analysis Population n of AEs n (%) of patients with AEs
AEs (including SAEs) 206 58 (77.3)
SAEs 30 24 (32.0)
AEs leading to death - -
Drug related AEs 37 21 (28.0)
AEs leading drug withdrawal 21 17 (22.7)
AEs with a frequency > 5% n (%)




Metabolic acidosis 7 (9.3)
Urinary tract infection 6 (8.0)
Hyperparathyroidism secondary 5 (6.7)
Pruritus 5 (6.7)
Blood pressure increased 4 (5.3)
Hyperlipidemia 4 (5.3)
Hyperphosphatemia 4 (5.3)
Back pain 4 (5.3)
AEs leading drug withdrawal  
Thrombocytosis 1 (1.3)
Diabetic retinopathy 1 (1.3)
Nausea 1 (1.3)
Chest pain 1 (1.3)
Pyelonephritis acute 1 (1.3)
Blood creatine increased 2 (2.7)
Blood creatinine increased 1 (1.3)
Creatinine renal clearance decreased 1 (1.3)
Diabetic foot 1 (1.3)
Hypervolemia 1 (1.3)
Metabolic acidosis 6 (8.0)
Renal failure 1 (1.3)
Renal failure acute 1 (1.3)
Dyspnea exertional 1 (1.3)
Hemodialysis 1 (1.3)
AE: adverse event; SAE: serious adverse event
TABLE 5. Overview of adverse events in safety population (n=75)
nantly of females compared with past studies in pre-dialysis 
patients (15-17), our findings revealed the similar efficacy of 
once-monthly subcutaneous C.E.R.A. in the correction and 
maintenance of Hb levels in pre-dialysis ESA-naïve patients. 
This seems to indicate the efficacy of C.E.R.A among pre-
dialysis anemic patients to be independent of patient demo-
graphics including age and gender. 
Data from two observational studies indicate the efficacy 
of C.E.R.A. in treatment of CRA among predialysis CKD pa-
tients in real life clinical practice with an increase in Hb levels 
from 10.7±1.4 g/dL to 11.5±1.2 g/dL (21) and an overall in-
crease of 1 g/dL (22) in ESA-naïve patients during 12-month 
and 9 months of follow up, respectively. 
In fact, 6-month C.E.R.A. treatment was reported to achieve 
a more marked increase in hemoglobin levels in kidney trans-
plant recipients compared with short-acting ESA (14). There-
fore, C.E.R.A treatment seems to be effective in all cases of 
CRA, regardless of the stage of the disease (17,21,22) or mo-
dality selected for renal replacement therapy (9,11,14,18-20).
In our study population, Hb levels improved from the base-
line level of 9.4 (0.4) g/dL to the time-adjusted average level 
of 11.4 (0.7) g/dL in the PP population, while from 9.3 (0.5) 
g/dL to 11.1 (1.0) g/dL in the ITT population, with a similar 
change from baseline to EEP of 2.0 (0.7) g/dL and 1.7 (1.1) g/
dL, respectively.
Hemoglobin target has been recommended as 11-12 g/dL by 
2012 National Kidney Foundation Disease Outcomes Quality 
Initiative (NKF-KDOQI) guidelines (23), while it is 10-12 g/
dL according to the European Medicine Agency (EMA) (24). 
Notably, time-adjusted average Hb was maintained within the 
target range of 10.0-12.0 g/dL in 73.2% of our patients in the 
PP population (95% Cl 57.1-85.8%), while only 54.7% of pa-
tients (95% Cl 42.8-66.2%) in the ITT population. This lower 
result in the ITT population can be explained by the possibil-
ity of missing a study drug administration for patients in the 
ITT population, whereas patients in the PP population were 
not permitted to miss a study drug administration. This seems 
notable given the suggested potential of achieving stable Hb 
concentrations in terms of increased health benefits to patients 
as well as reduction in the frequency of healthcare interven-
tions (4).
Monthly C.E.R.A therapy was also shown to achieve Hb 
levels of 10-12g/dL in the evaluation period in 50% of pre-
dialysis patients with CRA (17). Given the lower likelihood 
of increasing Hb levels beyond the recommended targets 
(>13 g/dL) in pre-dialysis patients within the first 8-weeks of 
C.E.R.A (12.4%) than darbepoetin alpha (33.5%) treatment 
(15), C.E.R.A treatment of anemia seems to retain the range 
of targeted Hb levels by offering a more gradual increase in 
Hb levels (20) as well as more stabilized Hb levels (15,17).
Given the percent of patients who needed dose changes 
during EEP (56.1% in PP and 49.1% in ITT population) and 
LTSP (59.0% in PP and 54.0% in ITT population) in the pres-
ent study, our findings seem consistent with data on the main-
tenance of stable target Hb levels (11-12 g/dL) under C.E.R.A. 
within a 12-month extension period with no need for dose ad-
justments in nearly 30% of patients (4).
In this regard, our findings related to requirement of dose 
adjustment during the DTP in 85.4% and 82.7% of patients 
in the PP and ITT populations, respectively with the need for 
an increase as well as a decrease in dose during the titration 
period in 46.3% and 49.3% of patients, respectively, empha-
size the role of careful titration of the drug dose for adequate 
treatment. 
Increased risk for hypertension, thrombosis and cardiovas-
cular events has been considered amongst the potential non-
erythropoietic effects of C.E.R.A therapy in CKD patients 
(25-27). In this regard, the lack of abnormalities in other 
laboratory parameters investigated in our patients during the 
course of C.E.R.A. therapy seems to indicate the target Hb 
concentration used in our study population to be appropriate 
in terms of risk/benefit assessment (28). 
In a past meta-analysis in anemic CKD patients treated 
with recombinant human erythropoietin, a higher Hb target 
of 12-16 g/dL was reported to be associated with increased 
risk of all-cause mortality, arterio-venous access thrombosis 
and poorly controlled hypertension (28). Hence, it is worth 
noting that hypertension was the most frequently encountered 
adverse event in our population.
In general, C.E.R.A. was documented to be well tolerated, 
with no association of the pattern of AEs with the dosage or 
schedule of regimen (4). In a recent meta-analysis of phase 
II-III data on C.E.R.A treatment, C.E.R.A was determined to 
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                     Baseline                      Week 48 
 N Mean (SD) N Mean (SD) p
Albumin (g/L) 75 37.7 (5.7) 46 37.8 (4.1) 0.9177
C reactive protein (mg/L) 70 8.8 (12.8) 40 7.8 (8.7) 0.6615
Creatinine (µmol/L) 75 289.6 (104.1) 47 323.8 (133.4)* 0.1163
Phosphate (mmol/L) 71 1.4 (0.3) 45 1.5 (0.3) 0.0829
Potassium (mmol/L) 75 4.9 (0.6) 47 4.9 (0.7) 1.0000
Ferritin (µg/L) 73 281.6 (163.2) 43 238.9 (136.6) 0.1518
Iron (µmol/L) 75 14.4 (10.3) 46 14.8 (5.7) 0.8096
TIBC (µmol/L) 75 44.1 (12.6) 46 44.7 (12.8) 0.8009
TSAT (%) 75 37.2 (42.2) 46 35.4 (17.7) 0.7842
*last measurement was at week 36 according to the protocol
TIBC: total iron-binding capacity; TSAT: transferrin saturation, SD: standard deviation
TABLE 6. Blood biochemistry and iron parameters in the safety population
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be associated with significantly lower rates of AEs and SAEs 
as compared with other ESAs (29). Likewise, our study con-
firmed the good safety and tolerability profile of C.E.R.A with 
the mean cumulative total dose up to week 44 of 1016 (720.2) 
μg and there were 206 adverse events in 58 (77.3%) patients 
overall. Thirty SAEs were recorded in 24 (32.0%) patients, 
two of which were identified to be drug-related. Notably, me-
tabolism and nutrition disorders (10.7%), metabolic acidosis 
in particular (8.0%), were the adverse events most common-
ly associated with treatment withdrawal. The occurrence of 
gradual rather than abrupt increase in Hb levels and stabiliza-
tion in the follow up seems to have a role in the good safety 
profile offered by C.E.R.A. 
Management of anemia has been considered challenging, 
involving the frequent administration of conventional ESAs 
along with the need for Hb monitoring and dose adjustments 
(4,26,27). Given the complexity of clinical management of 
dialysis patients, the introduction of extended administration 
intervals and less frequent dose changes has been considered 
to offer a simplified and less time-consuming care and thus to 
allow the fair distribution of healthcare resources along with a 
reduction in healthcare costs (4,30). 
Certain limitations to this study should be considered. First-
ly, the lack of a placebo or comparison group consistent with 
a single-arm open-label design of the study seems to be the 
major limitation. The inclusion of patients followed by nine 
different centers located in diverse geographical regions of 
our country and high statistical power (100%) in the post-
hoc power analysis increase the ability of our study results 
to reflect the pre-dialysis patients countrywide, whereas high 
premature discontinuation rates and predominance of female 
patients in our cohort limits the extension of the knowledge 
achieved in the current study other and racial differences 
should also be considered while interpreting our results for 
other populations. Secondly, one must remain prudent when 
interpreting our findings on the safety and tolerability profile, 
given the inclusion of a very homogeneous patient popula-
tion with GFR<30 mL/min and the relatively small sample 
size. Nevertheless, limiting the likelihood of the introduction 
of selection bias for more responsive or unresponsive patients, 
patients with CRA were treatment-naïve in terms of RRT and 
ESA treatment prior to C.E.R.A. and our findings provide data 
on the effect of C.E.R.A. in a very homogeneous population 
(only patients with GFR <30 mL/min) of patients with pre-
dialytic CKD, and thus represent a valuable contribution to 
the available literature. 
In conclusion, our findings demonstrate that the use of once-
monthly subcutaneous C.E.R.A. is effective in the correction 
and maintenance of Hb levels in pre-dialysis CRA patients.
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